A new federal ruling means that patients will no longer have access to cheaper versions of Eli Lilly weight loss and diabetes ...

Following a similar decision in case the trade group Outsourcing Facilities Association brought against FDA over its decision ...

As the FDA halts the sale of Ozempic and Zepbound copycats, online clinics have begun offering liraglutide, an older GLP-1 ...

Ever since the pharmaceutical company Novo Nordisk realized that GLP-1 drugs were useful for more than diabetes, doctors and ...

Some of the bankrupt company’s closest rivals, newer telehealth firms, face a new challenge of their own as federal ...

President Donald Trump is under pressure to decide how widely available anti-obesity drugs should be and whether Medicare ...

In March this year, U.S. pharma giant Eli Lilly And Co (NYSE:LLY) announced the launch of its popular weight loss drug Mounjaro ... notes that Indian patients no longer need to depend on the ...

Investors are worried Novo Nordisk's competition with Eli Lilly is heating up and that the first-to-market GLP-1 leader is ...

A new study shows that people Zepbound lost about 50% more weight than those using Wegovy. It was the first head-to-head ...

Eli Lilly’s (LLY) and Novo Nordisk’s (NVO) weight loss drugs went head-to-head in a weight loss study for the first time — ...